NCT05568225

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Forma Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk MDS.

Conditions

• Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R

Interventions

Type	Name	Description
DRUG	Etavopivat	400 mg once daily

Timeline

• Start date: 2022-11-15
• Primary completion: 2024-07-15
• Completion: 2024-07-15
• First posted: 2022-10-05
• Last updated: 2025-10-22
• Results posted: 2025-10-22

Locations

18 sites across 4 countries: United States, Canada, France, Germany

Regulatory

• FDA-regulated drug study